Ribociclib plus endorcrine therapy led to a statistically significant improvement in progression-free survival in patients with hormone receptor–positive, HER2-negative unresectable or metastatic breast cancer with tumor progression following treatment with a CDK4/6 inhibitor, according to findings from the randomized phase 2 MAINTAIN trial.
SOT101 Displays Antitumor Activity Alone and With Pembrolizumab in Advanced Solid Tumors
June 4th 2022SOT101 alone and in combination with pembrolizumab demonstrated a favorable safety profile with no additional toxicities reported and promising efficacy among patients with advanced solid tumors, according to findings from the phase 1 AURELIO-03 trial.
Palbociclib Plus Letrozole Misses OS End Point in ER+/HER2- Advanced Breast Cancer
First-line treatment with palbociclib plus letrozole did not elicit a significant benefit in overall survival compared with letrozole monotherapy in patients with estrogen receptor-positive/HER2-negative advanced breast cancer missing the secondary end point of the trial.
Trastuzumab Deruxtecan Remains Safe and Effective Option for Metastatic Breast Cancer
Updated data from a safety analysis of the phase 3 DESTINY-Breast03 study confirmed the tolerability of trastuzumab deruxtecan among patients with with HER2-positive unresectable or metastatic breast cancer.
Epcoritamab Plus R2 Elicits High Metabolic Response Rate in Relapsed/Refractory Follicular Lymphoma
The addition of subcutaneous epcoritamab to treatment with rituximab and lenalidomide resulted in a 100% response rate and a low incidence of low-grade cytokine release syndrome in patients with relapsed/refractory follicular lymphoma, according to findings from arm 2 of the EPCORE NHL-2 trial.
Dr. Falchi on the Use of Epcoritamab with R-CHOP Therapy in High-Risk DLBCL
June 4th 2022Lorenzo Falchi, MD, discusses the updated findings from the phase 1/2 EPCORE NHL-2 trial trial evaluating the subcutaneous administration of epcoritamab with R-CHOP in patients with high-risk diffuse large B-cell lymphoma.
ctDNA Demonstrates Efficacy as Treatment-Decision Tool for Adjuvant Chemotherapy in Colon Cancers
Guided approaches leveraging circulating tumor DNA status can reduce the number of patients who receive adjuvant chemotherapy without the risk of lowering recurrence-free survival rates for some patients with stage II colon cancer.
Long-Term Follow-Up Supports Acalabrutinib-Based Regimens in Treatment-Naïve CLL
June 4th 2022At approximately 5 years of follow-up, findings from the phase 3 ELEVATE-TN study show that treatment outcomes are more favorable with acalabrutinib with or without obinutuzumab compared with obinutuzumab and chlorambucil in treatment-naïve chronic lymphocytic leukemia.
BTX-1188 Demonstrates Safety Benefits, Enters Phase 1 Trials in AML and Solid Tumors
June 4th 2022BTX-1188, a first-in-class oral molecular glue, is undergoing investigation in phase 1 clinical trials in patients with solid tumors or acute myeloid leukemia, after preclinical trials supported its potential safety benefits in this population and demonstrated its high sensitivity in Myc-driven cancer cell lines.
Epcoritamab Plus R-CHOP Shows Efficacy and Tolerability as First-Line Treatment for High-Risk DLBCL
June 4th 2022The addition of subcutaneous epcoritamab to standard-of-care R-CHOP demonstrated clinically meaningful response in the first-line treatment of patients with high-risk diffuse large B-cell lymphoma according to updated results of a single-arm of the EPCORE NHL-2 trial.
Magrolimab Plus Azacitidine Elicits Manageable Anemia in HR-MDS
June 4th 2022Magrolimab plus azacitidine, at priming and maintenance doses, enables manageable anemia in patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia, according to results from a prospective phase 1 study (NCT03248479).
Addition of Ivosidenib to Azacitidine Improves Outcomes in Newly Diagnosed IDH1-Mutant AML
The combination of ivosidenib and azacitidine elicited a clinically meaningful benefit across end points compared with azacitidine alone among patients with newly diagnosed IDH1-mutant acute myeloid leukemia who were ineligible for intensive induction chemotherapy.
Glofitamab Demonstrates Durable Response in Heavily Pretreated Large B-Cell Lymphoma
Glofitamab elicited an objective response rate of 51.6% when administered for a fixed duration among patients with patients with heavily pretreated, highly refractory large B-cell lymphoma, regardless of prior CAR T-cell therapy exposure, according to findings from a phase 2 expansion study.
Atezolizumab Plus Cabozantinib Elicits Clinical Activity in Advanced Urothelial Cancer
June 4th 2022Cabozantinib plus atezolizumab demonstrated promising clinical activity and a suitable safety profile as first-line therapy in patients with cisplatin- eligible and -ineligible, inoperable locally advanced or metastatic urothelial cancer and as second- or later-line therapy in those who received a prior immune checkpoint inhibitor, according to findings from the phase 1b COSMIC-021 trial.
Single-Agent Cabozantinib Stalls as Maintenance Therapy in Advanced Urothelial Cancer
June 4th 2022Results of the ATLANTIS study do not support further investigation of cabozantinib alone as a maintenance therapy after platinum-based chemotherapy in unselected patients with advanced urothelial cancer.
Frontline Brentuximab Vedotin Plus Chemotherapy Improves 6-Year Survival in Hodgkin Lymphoma
June 3rd 2022Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine demonstrated a significant reduction in the risk of death vs doxorubicin, bleomycin, vinblastine, and dacarbazine, with a manageable safety profile consistent with prior findings in patients with previously untreated stage III/IV classical Hodgkin lymphoma.
Superior Survival Benefit With Ramucirumab Plus Pembrolizumab Observed in ICI-Resistant NSCLC
June 3rd 2022The addition of ramucirumab to pembrolizumab elicited significant response among patients with advanced non–small cell lung cancer who experienced disease progression following treatment with PD-1/PD-L1 inhibitors and platinum-based doublet chemotherapy.
Adagrasib Elicits Deep and Durable Responses in Pretreated KRAS G12C–Mutant NSCLC
June 3rd 2022Adagrasib led to early onset and deep responses translating to encouraging survival as a single agent in previously treated patients with KRAS G12C–mutated non–small cell lung cancer, according to results from cohort A of the phase 1/2 KRYSTAL-1 trial.